Previous 10 | Next 10 |
home / stock / kaltf / kaltf news
SAN FRANCISCO, May 25, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the " Company " or " Kalytera ") today issued the following letter to shareholders from the Company’s President and CEO, Robert Farrell. Dear Kalytera Shareholders, I...
Kalytera Therapeutics ( OTCQB:KALTF ) has signed a letter of intent to acquire privately held Salzman Group, the owner of R-107, a liquid prodrug of nitric oxide being developed to treat COVID-19-associated lung disease, chlorine inhalation lung injury and pulmonary arterial hypertension. ...
SAN FRANCISCO, May 19, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the " Company " or " Kalytera ") announced today that it has signed a binding Letter of Intent dated May 12, 2020 (the “LOI”) to acquire Salzman Group, Inc.,...
SAN FRANCISCO, April 28, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") is providing an update on the status of the filing of its annual financial statements for the fiscal year ending December 31, 2019 and the interi...
SAN FRANCISCO, April 13, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the " Company " or " Kalytera ") has announced that it will not proceed with the previously announced acquisition of Stero Biotechs, Ltd. ( “Stero” ), and that St...
SAN FRANCISCO and TEL AVIV, Israel, March 18, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the " Company " or " Kalytera ") today provided additional details regarding the terms of its planned acquisition of Stero Biotechs, Ltd. ( “Stero...
SAN FRANCISCO, Calif. and TEL AVIV, Israel, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the " Company " or " Kalytera ") today announced a modification to the sale period contemplated by the irrevocable selling agreement between Salzman...
SAN FRANCISCO and TEL AVIV, Israel, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the " Company " or " Kalytera ") today announced that it has completed the previously announced transaction under the payments agreement with the Salzman Gr...
SAN FRANCISCO and TEL AVIV, Israel, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the " Company " or " Kalytera ") today announced that it has entered into a new agreement reached with the Salzman Group of Israel (the “Agreement...
SAN FRANCISCO and TEL AVIV, Israel, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the " Company " or " Kalytera ") today announced that the United States Patent and Trademark Office (the “ USPTO ”) has issued a Notice of All...
News, Short Squeeze, Breakout and More Instantly...
Kalytera Therapeutics Company Name:
KALTF Stock Symbol:
OTCMKTS Market:
Kalytera Therapeutics Website:
SAN FRANCISCO, CA and TORONTO, ON , Feb. 22, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that it has received comments from the Australian Human Research Ethics Committee (the “...
SAN FRANCISCO, CA and TORONTO, ON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that the Australian Human Research Ethics Committee (HREC) will meet on February 16 th to...
SAN FRANCISCO, CA and TORONTO, ON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the “ Company ” or “ Claritas ”) today announced revised, improved pricing for the initial tranche of funds that the Co...